AstraZeneca insisted Wednesday that its COVID-19 vaccine is strongly effective even after counting additional illnesses in its disputed US study, the latest in an extraordinary public rift with American officials.
In a late-night press release, AstraZeneca said it had recalculated data from that study and concluded the vaccine is 76 percent effective in preventing symptomatic COVID-19, instead of the 79 percent it had claimed earlier in the week.
Just a day earlier, an independent panel that oversees the study had accused AstraZeneca of cherry-picking data to tout the protection offered by its vaccine. The panel, in a harsh letter to the company and to US health leaders, said the company had left out some COVID-19 cases that occurred in the study, a move that could erode trust in the science.
Data disputes during ongoing studies usually remain confidential but in an unusual step, the National Institutes of Health publicly called on AstraZeneca to fix the discrepancy.
AstraZeneca had been counting on findings from a predominantly US study of 32,000 people to help rebuild confidence in a vaccine that, despite being widely used in Britain, Europe and other countries, has had a troubled rollout. Previous studies have turned up inconsistent data about its effectiveness, and then last week a scare about blood clots had some countries temporarily pausing inoculations.
Now the question is whether the company’s newest calculations end the tension.
Earlier Wednesday, Dr. Anthony Fauci, the top US infectious disease expert, told reporters he hoped that when all the data was publicly vetted by federal regulators, it would dispel any hesitancy caused by the spat. He predicted it would “turn out to be a good vaccine.”
AstraZeneca’s newest calculations were based on 190 COVID-19 cases that occurred during the study, 49 more than it had included earlier in the week. The vaccine appears especially protective against the worst outcomes, with no severe illnesses or hospitalizations among vaccinated study volunteers compared to eight severe cases among those given dummy shots, the company said. It didn’t provide a breakdown of the rest of the cases.
European authorities had questioned how protective the vaccine is in older adults. In the US study, it was 85 percent effective in volunteers 65 and older, the company said. The study didn’t turn up safety concerns.
The updated information “confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over,” AstraZeneca research chief Mene Pangalos said in a statement. He said the company looks forward to “the rollout of millions of doses across America.”
The study hasn’t ended so additional COVID-19 cases can accrue. AstraZeneca cautioned that 14 additional possible cases already are being examined, which could lead to further changes in the data.
The company intends to seek Food and Drug Administration clearance of the vaccine within a few weeks. The FDA will publicly debate all the evidence with its outside advisers before making a decision.
AstraZeneca may have included outdated info from US COVID-19 vaccine trial: NIAIDBritish drugmaker AstraZeneca Plc may have provided an incomplete view of efficacy data on its COVID-19 vaccine from a large scale US trial, the US ... Coronavirus
EU points finger at AstraZeneca in vaccine supply row with UKBritain on Monday demanded the European Union allow the delivery of COVID-19 vaccines it has ordered as tensions over a possible export ban on ... Coronavirus
AstraZeneca-Oxford COVID-19 vaccine 79 pct effective in US trialThe COVID-19 vaccine developed by Oxford University and AstraZeneca was 79 percent effective in preventing symptomatic illness a large trial in the ... Coronavirus